Dana-Farber Cancer InstituteBoston, Massachusetts, United States
Disclosure information not submitted.
Paper 61 - INSIGHT: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF RIPRETINIB VS SUNITINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR PREVIOUSLY TREATED WITH IMATINIB WITH KIT EXON 11+17/18 MUTATIONS
Saturday, November 4, 20239:00 AM – 10:00 AM
Paper 72 - GENOMIC EVOLUTION OF RESISTANCE IN GASTROINTESTINAL STROMAL TUMOR: KIT AP/AL MUTATIONS ARE A KEY MECHANISM OF KINASE-INHIBITOR ESCAPE
Saturday, November 4, 202311:30 AM – 1:00 PM
Paper 84 - A PHASE 2 STUDY OF ROGARATINIB (BAY 1163877) IN SOFT TISSUE SARCOMAS: INITIAL RESULTS IN COHORT OF PATIENTS WITH SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST)
Saturday, November 4, 20233:00 PM – 4:00 PM
